Research is not wavering.
While last week the WHO announced the start of new tests on three drugs to treat Covid-19, the European Medicines Agency indicates this Thursday to test RoActemra, an anti-inflammatory.
The latter could be used to treat, in hospitals, adult patients with a severe form of Covid, who have already received corticosteroid treatment and placed on oxygen.
“RoActemra is considered a potential treatment for Covid-19 due to its ability to block the action of interleukin-6, a substance produced by the body's immune system in response to inflammation, which plays a role important in the Covid-19.
», Explains the European Agency in a press release.
The European Medicines Agency will carry out an "accelerated evaluation" of RoActemra and communicate on the result of its evaluation, which is expected "by mid-October, unless additional information is required.
"
RoActemra was authorized in the European Union in 2009.